scripvibha's profile picture. Senior Editor, Citeline - Scrip, Pink Sheet. Tweets on pharma, health, environment, other topics of interest to those who read beyond headlines, social media

Vibha Ravi

@scripvibha

Senior Editor, Citeline - Scrip, Pink Sheet. Tweets on pharma, health, environment, other topics of interest to those who read beyond headlines, social media

Pinned

As US companies increase DTC advertising and FDA gets into scrutiny mode, how can pharma "shift left” with agentic AI, balance compliance and creativity? #regulatory #Marketing #biotech @indegeneinsight insights.citeline.com/pink-sheet/com…


Cipla to acquire Inzpera, Indian maker of pediatric pharma and wellness products for INR1.1bn #acquisition #deals #pharma bseindia.com/xml-data/corpf…


Vibha Ravi reposted

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/49ni5 vist.ly/49ni6


Lupin strengthens global specialty portfolio with €190m VISAfarma acquisition in Europe #acquisition #deals #pharmaceuticals


Trump: 100% tariff on any branded or patented pharma product unless manufacturing plant being built in the US. "Branded" definition needed before further comment. Wrote this before the announcement #tariff #BusinessNews #pharmatariff #Biotech insights.citeline.com//pink-sheet/ma…


Vibha Ravi reposted

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/46n39 vist.ly/46n3a


Vibha Ravi reposted

Under new owner Bain Capital, the Japanese firm is aiming to regain its global presence, helped by new top executives formerly with Pfizer Japan and Takeda. insights.citeline.com//scrip/focus-o…


Vibha Ravi reposted

Multiple Korean ministries, biopharma companies, and other officials convened at a bio innovation roundtable to discuss strategies to emerge as a global biopharma powerhouse, @PharmaPinkSheet reports. insights.citeline.com/pink-sheet/r-a…


Vibha Ravi reposted

China NHSA Releases Preliminary Innovative Drug List For First Time — Click image below to read more! || #PinkSheet | Start your free trial today: vist.ly/44prp vist.ly/44prq


Vibha Ravi reposted

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality. insights.citeline.com//scrip/advance…


Vibha Ravi reposted

In this episode: Madrigal regains MASH lead with EU Rezdiffra approval; Viking’s obesity data scare investors; China assets lead GLP-1 deals; CSL and others restructure; and Indegene exec on DTP and MFN policies.

Quick Listen: Scrip’s Five Must-Know Things — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/44f7t vist.ly/44f7u



50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray. This is what we had said. Now 50% tariffs come into effect from Aug. 27 as US Customs issues notice #TariffsOnIndia #Tariffs #TradeWar #BusinessStrategy insights.citeline.com//pink-sheet/ma…


An interview with OneSource CEO, MD Neeraj Sharma reveals he isn't just counting on semaglutide (Novo's Wegovy, Ozempic) but is talking to next-gen GLP-1 innovators for growth #BusinessNews #Strategy @strides_pharma insights.citeline.com//scrip/leaders…


Vibha Ravi reposted

Quick Listen: Scrip’s Five Must-Know Things — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/43nvi vist.ly/43nvj


Always great to have a vote of confidence from a person you look up to. Thanks @ScripIanHaydock

Excellent data- and infographics-supported analysis of the impact of #tariffs on #pharma in India and beyond by @scripvibha for @PharmaPinkSheet



Why does Aurobindo expect US-based Lannett's acquisition to pass FTC scrutiny? How does it help to reduce tariffs? Read to know #business #Tariffs #Acquisition insights.citeline.com//scrip/busines…


Loading...

Something went wrong.


Something went wrong.